Physician profile
Zachary Bryan
NPI 1760876684
$744.33
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $259.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $290.96 | 2019-2020 | |
| Allergan, INC. | $97.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $74.69 | 2019-2020 | |
| Janssen Biotech, INC. | $55.03 | 2019-2020 | |
| Genzyme Corporation | $39.87 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $37.44 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.81 | 2019-2020 | |
| Ucb, INC. | $26.24 | 2020 | |
| Leo Pharma INC. | $21.93 | 2020 | |
| Amgen INC. | $16.42 | 2020 | |
| Sun Pharmaceutical Industries INC. | $15.89 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.16 | 2019 | |
| Lilly USA, LLC | $14.16 | 2020 | |
| Pfizer INC. | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.